- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
JHL Biotech Doses First Patients in Denosumab Trial
Taiwan-based JHL Biotech said it has initiated a phase 1 clinical trial of its denosumab biosimilar candidate for bone loss.
Hsinchu, Taiwan—based JHL Biotech said it has initiated a phase 1 clinical trial of its denosumab biosimilar candidate JHL 1266, having randomized and treated the first group of patients.
JHL 1266 is a monoclonal antibody targeting RANKL, a gene that regulates cell death. Denosumab inhibits the development of osteoclasts, which break down bone tissue and release the minerals into the blood stream. The drug thereby prevents breakdown of bones in the human body.
Denosumab is used for the treatment of osteoporosis and hypercalcemia, or above-normal calcium levels. In the United States it is indicated for osteoporosis and improving bone mass in individuals at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.
The company said the 3-arm study is being conducted in Australia and will compare the pharmacokinetic similarity of JHL 1266 with that of the reference product, Prolia, in healthy patients. The company described the study as pivotal for regulatory approval.
“Denosumab is an important biologic for the treatment of post-menopausal osteoporosis and other common bone related diseases. Because it’s unfortunately very expensive for patients and healthcare payers, JHL1266 would provide an affordable treatment for these patients,” said James Huang, CEO of JHL Biotech, in a statement.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
